EMA: Insufficient data linking GSK vax with narcolepsy; Greece cuts more brands from formulary;

@FiercePharma: Generics makers need to change their spots--and learn marketing--to sell biosimilars, Actavis CEO says. More | Follow @FiercePharma

> European regulators wrapped up a safety review of GlaxoSmithKline's ($GSK) flu shot Pandemrix, saying evidence linking it with narcolepsy is "insufficient." Report

> Greece dropped plans to claw back pharma industry revenues to make up for overspending on outpatient drug therapy, but apparently cut some branded drugs from its new formulary. Report

> U.S. officials confirmed that a deadly fungus implicated in a meningitis outbreak was present in one lot of steroids supplied by New England Compounding Center. Report

> The FDA plans to allow Sun Pharmaceuticals to continue importing its version of the Johnson & Johnson ($JNJ) cancer drug Doxil until the branded product shortage completely resolves. Report

> AstraZeneca ($AZN) won a £5 million investment from a U.K. government fund to back its efforts toward a potential BioScience cluster at its R&D facility in Alderley Park. Report

Medical Device News

 @FierceMedDev: VC investment in Q3 is way down for medical devices. More | Follow @FierceMedDev

 @MarkHFierce: So what were the top med device VC deals in the 2012 third quarter? More | Follow @MarkHFierce

 @DamianFierce: Steris is spending $110M on M&A to expand its surgical device capabilities. More | Follow @DamianFierce

> Complete Genomics scores patent win over Illumina. Story

> Study: To reduce heart disease risks, gastric banding beats drugs. News

> Sony slashes jobs on road to medical device focus. Item

Biotech News

 @FierceBiotech: Wanted: Premier hepatitis C drug developer to partner with Vertex. More | Follow @FierceBiotech

 @JohnCFierce: $1.2B in VC for biotech in Q3 not the best ever, but a whole lot more than we've been seeing--so I see it as a solid +. More | Follow @JohnCFierce

> Novo's long-acting insulin degludec takes big step to megamarket status. Story

> Wanted: Premier hepatitis C drug developer to partner with Vertex. News

> U.K.'s Redx blueprints big R&D spinoff funded by government grant. Article

And Finally... Blood hormone tests predicted a woman's risk for developing postmenopausal breast cancer for up to 20 years, a new study found. Report

Suggested Articles

Cannes Lions Health kicks off Monday, and attendees are looking for some breakouts—leading-edge tech, creativity and inspiration, for instance.

Bluebird has priced gene therapy Zynteglo at €1.575 million in Europe and promised a U.S. price in “reasonably close” range.

Generic pain drug maker Lannett is closing its plant in Wyoming and laying off the remaining 80 employees.